Clinical trial
ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL
NCT04603183
Study timeline
Study start (actual)2021-06-02Date precision: day
Registry last updated2025-12-12
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast Cancer Metastaticunresolved
Interventions
AbemaciclibDRUG · verified · RxNorm: abemaciclib
PaclitaxelDRUG · verified · RxNorm: paclitaxel
LetrozoleDRUG · verified · RxNorm: letrozole
FulvestrantDRUG · verified · RxNorm: fulvestrant
Sponsors & collaborators
MedSIRlead sponsor
Eli Lilly and Companycollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04603183 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.